These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 19941277

  • 1. [Treatment of secondary hyperparathyroidism in dialysis patients].
    Di Luca M.
    G Ital Nefrol; 2009; 26 Suppl 49():S36-48. PubMed ID: 19941277
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. [Cardiovascular effects of VDR and CaSR activation].
    Brancaccio D, Cozzolino M.
    G Ital Nefrol; 2009 Nov; 26 Suppl 49():S18-22. PubMed ID: 19941274
    [Abstract] [Full Text] [Related]

  • 4. [Cardiovascular calcification and accelerated atherosclerosis in chronic kidney disease].
    Cozzolino M, Butti A, Chiarelli G, Rocca-Rey L, Santagostino G, Gallieni M, Brancaccio D.
    Ital Heart J Suppl; 2005 Jan; 6(1):25-8. PubMed ID: 15776728
    [Abstract] [Full Text] [Related]

  • 5. [Prevention and treatment of secondary hyperparathyroidism in non-dialyzed patients with stage 3-5 chronic kidney diease].
    Cozzolino M, Olivi L, Voli E, Ciceri P, Brancaccio D.
    G Ital Nefrol; 2009 Jan; 26 Suppl 49():S30-5. PubMed ID: 19941276
    [Abstract] [Full Text] [Related]

  • 6. [Selective vitamin D receptor activation: effect on renal physiopathology].
    Marangella M, Berutti S, Fabbrini L.
    G Ital Nefrol; 2009 Jan; 26 Suppl 49():S23-9. PubMed ID: 19941275
    [Abstract] [Full Text] [Related]

  • 7. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease.
    Sprague SM, Coyne D.
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):512-8. PubMed ID: 20133492
    [Abstract] [Full Text] [Related]

  • 8. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M, Brancaccio D.
    Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
    [Abstract] [Full Text] [Related]

  • 9. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
    Brown AJ, Slatopolsky E.
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
    [Abstract] [Full Text] [Related]

  • 10. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.
    Brancaccio D, Bommer J, Coyne D.
    Drugs; 2007 Feb; 67(14):1981-98. PubMed ID: 17883283
    [Abstract] [Full Text] [Related]

  • 11. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease.
    Goodman WG.
    Semin Dial; 2004 Feb; 17(3):209-16. PubMed ID: 15144547
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Role of vitamin D in cardiovascular disease.
    Verhave G, Siegert CE.
    Neth J Med; 2010 Mar; 68(3):113-8. PubMed ID: 20308705
    [Abstract] [Full Text] [Related]

  • 14. Vitamin D receptor activator reduces oxidative stress in hemodialysis patients with secondary hyperparathyroidism.
    Tanaka M, Tokunaga K, Komaba H, Itoh K, Matsushita K, Watanabe H, Kadowaki D, Maruyama T, Otagiri M, Fukagawa M.
    Ther Apher Dial; 2011 Apr; 15(2):161-8. PubMed ID: 21426509
    [Abstract] [Full Text] [Related]

  • 15. Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies.
    Hudson JQ.
    Ann Pharmacother; 2006 Sep; 40(9):1584-93. PubMed ID: 16912241
    [Abstract] [Full Text] [Related]

  • 16. [CKD-MBD (chronic kidney disease-mineral and bone disorder). CKD-MBD: chronic kidney disease-mineral and bone disorder].
    Mizobuchi M, Aoshima Y, Akizawa T.
    Clin Calcium; 2010 Jul; 20(7):995-1003. PubMed ID: 20585177
    [Abstract] [Full Text] [Related]

  • 17. Secondary hyperparathyroidism: pathophysiology and treatment.
    Saliba W, El-Haddad B.
    J Am Board Fam Med; 2009 Jul; 22(5):574-81. PubMed ID: 19734404
    [Abstract] [Full Text] [Related]

  • 18. Vitamin D treatment in chronic kidney disease.
    Andress DL.
    Semin Dial; 2005 Jul; 18(4):315-21. PubMed ID: 16076355
    [Abstract] [Full Text] [Related]

  • 19. Calcitriol in the management of secondary hyperparathyroidism of renal failure.
    Daisley-Kydd RE, Mason NA.
    Pharmacotherapy; 1996 Jul; 16(4):619-30. PubMed ID: 8840368
    [Abstract] [Full Text] [Related]

  • 20. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
    Capuano A, Serio V, Pota A, Memoli B, Andreucci VE.
    J Nephrol; 2009 Jul; 22(1):59-68. PubMed ID: 19229819
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.